Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2018 Jul 18.
Published in final edited form as: Nat Genet. 2011 Jul 17;43(8):738–740. doi: 10.1038/ng.884

Mutations in NBEAL2, encoding a BEACH protein, cause gray platelet syndrome

Walter HA Kahr 1,2,3,#, Jesse Hinckley 4, Ling Li 2, Hansjörg Schwertz 5, Hilary Christensen 2, Jesse W Rowley 6, Fred G Pluthero 2, Denisa Urban 2,3, Shay Fabbro 4, Brie Nixon 4, Rick Gadzinski 7, Mike Storck 7, Kai Wang 8, Gi-Yung Ryu 9, Shawn M Jobe 10, Brian C Schutte 11, Jack Moseley 12, Noeleen B Loughran 13, John Parkinson 13, Andrew S Weyrich 6, Jorge Di Paola 4,#
PMCID: PMC6050511  NIHMSID: NIHMS595414  PMID: 21765413

Abstract

Next-generation RNA sequence analysis of platelets from an individual with autosomal recessive gray platelet syndrome (GPS, MIM139090) detected abnormal transcript reads, including intron retention, mapping to NBEAL2 (encoding neurobeachin-like 2). Genomic DNA sequencing confirmed mutations in NBEAL2 as the genetic cause of GPS. NBEAL2 encodes a protein containing a BEACH domain that is predicted to be involved in vesicular trafficking and may be critical for the development of platelet α-granules.


GPS is characterized by variable thrombocytopenia and large platelets that lack α-granules but have normal dense (δ) granules, lysosomes, mitochondria and peroxisomes1. Genome-wide linkage analysis has mapped the GPS locus to within a 9.4-megabase region on chromosome 3p21 (refs. 2,3) containing 197 protein codinggenes3, of which 69 have been completely or partially sequenced2,3. Our analysis led us to target a 2.7-megabase region in three families affected with GPS, two of Native American and one of Pakistani ancestry. Microscopic analysis of GPS platelets confirmed the absence of α-granules and characterized their abnormal size, shape and protein distribution (Supplementary Fig. 1).

As platelets have a diverse repertoire of mRNAs4, we reasoned that GPS-associated aberrations or deficiencies in gene expression might be detected by examining platelet transcript expression patterns. We performed focused next-generation genome-wide RNA sequencing (RNA-seq) of platelet mRNA from an individual with GPS to look for atypical expression of transcripts derived from genes located within the target region that are suspected to be involved in cellular vesicular trafficking. We found an abnormal distribution of reads mapping to NBEAL2; specifically, NBEAL2 transcripts isolated from GPS platelets showed retention of introns (Fig. 1), indicating abnormal pre-mRNA processing.

Figure 1.

Figure 1

Abnormal sequence reads in NBEAL2 transcripts observed in platelet RNA from an individual with GPS. Snapshots shown from Integrated Genome Browser (IGB) for NBEAL2 transcripts expressed in platelets isolated from (top) a healthy donor and (bottom) an individual with GPS. Bar heights represent relative numbers of 50-base pair reads spanning NBEAL2; Refseq gene annotation for NBEAL2 is shown at the bottom. The red box outlines a region where introns are abnormally retained in NBEAL2 transcripts from platelets from the individual with GPS. See Supplementary Methods for details.

Sequencing of NBEAL2 in genomic DNA from the same individual detected a splice variant at position 1,029 (c.1029+1G>A) at the exonintron 9 boundary (family 1, Fig. 2). This mutation seems to prevent recognition of the 3́ splice site in exon 9, causing the retention of intron 9 in the mRNA and introducing three in-frame premature stop codons within 80 nucleotides of the putative splice site. This mutation was also identified in RNA-seq reads spanning the exon-intron 9 junction (Supplementary Fig. 2). We found a second mutation consisting of a five-base pair duplication of bases 4,371–4,375 in exon 28 (c.4371_4375dupCGTGG), which introduces an in-frame premature stop codon (TGA, nucleotides 4,496–4,499) 120 bases downstream. The duplication was also detected in the RNA-seq reads (data not shown). The compound heterozygous mutations were inherited from the parents (family 1, Fig. 2).

Figure 2.

Figure 2

Mutation analysis of NBEAL2. (a) Pedigrees for three GPS-affected families with mutation status shown beneath symbols for each individual. (b) Schematic of NBEAL2, which is composed of 54 exons encoding untranslated regions (yellow) and protein-coding sequences (blue; the BEACH domain is encoded by exons 37–45). Red arrows indicate the locations of mutations in the NBEAL2 genomic sequence found in individuals with GPS (chromatograms are shown in Supplementary Fig. 3).

Sequencing of genomic NBEAL2 in two other affected families identified a homozygous nonsense mutation at position 1,820 of exon 13 (c.1820G>A) that introduced a stop codon (Trp607X) in three affected individuals of family 2 (Fig. 2) and segregated with disease status (parents were heterozygous for the mutation). In family 3 (Fig. 2), all affected individuals showed heterozygosity for the 1820G>A mutation, as did the mother who is from the same settlement as family 2. As this family has a parent originating outside the settlement, we searched for a compound heterozygosity that could explain the phenotype and identified a one-base pair duplication of position 5,413 (c.5413dupG) in exon 33. This mutation was present only in the father and his two affected children, and the single-base frameshift introduced a TGA stop codon 172 bases downstream (bases 5,586–5,588). Mutations in the three families are summarized in Supplementary Table 1 and Supplementary Figure 3.

Premature stop codons caused by nonsense mutations, frameshifts or splice-site alterations are known to have deleterious effects on gene expression, including nonsense-mediated mRNA decay and, to a lesser extent, protein truncation5. Thus, our results indicate that NBEAL2 mutations are the main cause of autosomal recessive GPS.

NBEAL2 encodes a polypeptide of 2,754 amino acids with a predicted molecular weight of 302.5 kDa that shows similarity to the product of the LYST gene (encoding lysosomal trafficking regulator), which is mutated in Chediak-Higashi syndrome (CHS; MIM214500)6. CHS is characterized by a deficiency of platelet δ-granules7. Domain analysis (Supplementary Figs. 4 and 5) showed that, like LYST, NBEAL2 contains a concavalin A-like lectin domain8, a pleckstrin homology domain that is predicted to function in recruiting proteins to cellular membranes9, a BEACH (beige and CHS) domain10 and WD40 repeats, which have been implicated in a variety of cellular functions11. Phylogenetic analysis indicated that NBEAL2 and its close homolog NBEAL1 are members of an ancient family of BEACH domain-containing proteins related to neurobeachin (which is expressed in neurons) and LRBA (lipopolysaccharide-responsive and beige-like anchor protein, which is involved in LPS-responsive vesicle trafficking) but distinct from LYST (Supplementary Fig. 6). Our analysis indicates that during the emergence of animals, the ancestral NBEAL gene underwent duplication to produce the neurobeachin/LRBA and NBEAL subfamilies, whereas a more recent duplication in the craniate (vertebrate) lineage produced the NBEAL1 and NBEAL2 subfamilies.

LYST mutations predict that the LYST protein is involved in trafficking among lysosomes and lysosome-related organelles (platelet-granules) that interact with different partners12. Other BEACH domain-containing proteins have been linked to cellular vesicular trafficking, including Bph1, the product of the S. cerevisiae homolog of LYST13, LysB in Dictyostelium14 and bchs in Drosophila15. Thus, it is reasonable to suspect that, like LYST and other BEACH domain–containing proteins, NBEAL2 is involved in vesicular trafficking. Our results indicate that the emergence of the NBEAL2 gene family in the vertebrate lineage might have been key to the evolution of platelet α-granules as unique specialized organelles.

Supplementary Material

Supplementary Information

Acknowledgments

Acknowledgments

We thank the families that participated in this study. This work was supported by grants from the US National Institutes of Health (NIH) to J.D.P. (NIH HL084086–01), A.S.W. (NIH HL066277 and HL091283), J.W.R. (NIH T32 HL105321), B.C.S. and G.-Y.R. (NIH UL1RR024979), the Canadian Institutes of Health Research to W.H.A.K. (MOP-81208), J.P. and N.B.L. (MOP-84556), and the American Heart Association to H.S. (AHA 09BG1A2250381). We thank R. Wong from the Diabetes and Endocrinology Research Center Molecular Biology Core at the University of Colorado–Denver for sequencing assistance (grant NIH P30DK57516), the Bioinformatics and Molecular Evolution Group, Dublin City University for the use of their computational facilities and D. Lim for preparing figures.

Footnotes

Accession code. NBEAL2, Entrez Gene 23218.

AUTHOR CONTRIBUTIONS

Designed experiments: W.H.A.K., A.S.W., J.H. and J.D.P. Performed research, analyzed data: W.H.A.K., A.S.W., J.D.P., J.H., L.L., H.S., H.C., J.W.R., F.G.P., D.U., S.F., B.N., R.G., M.S., K.W., G.-Y.R., S.M.J., B.C.S., J.M., N.B.L. and J.P Wrote and edited manuscript: W.H.A.K., A.S.W., J.D.P., J.P, N.B.L., J.H., J.W.R. and F.G.P.

COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

References

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Information

RESOURCES